ArticleMolecules (Basel, Switzerland)2019
Next-Generation Sequencing Reveals the Role of Epigallocatechin-3-Gallate in Regulating Putative Novel and Known microRNAs Which Target the MAPK Pathway in Non-Small-Cell Lung Cancer A549 Cells.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Effects of Epigallocatechin Gallate Against Lung Cancer: Mechanisms of Action and Therapeutic Potential.Nutrients · 2026Review
- Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis.Frontiers in oncology · 2026Article
- Regulatory Effects of Coffee/Chlorogenic Acid and Tea/Epigallocatechin-3-Current issues in molecular biology · 2025Review
- Anticancer Molecular Mechanisms of Epigallocatechin Gallate: An Updated Review on Clinical Trials.Food science & nutrition · 2025Review
- Flavonoids in the Treatment of Non-small Cell Lung Cancer via Immunomodulation: Progress to Date.Molecular diagnosis & therapy · 2025Review
- Serum Reproductive Hormone Profiles and Endometrial Expression of miR-16-5p,Advanced biomedical research · 2025Article
- Plant bioactive compounds driven microRNAs (miRNAs): A potential source and novel strategy targeting gene and cancer therapeutics.Non-coding RNA research · 2024Article
- Regulation of gene expression by modulating microRNAs through Epigallocatechin-3-gallate in cancer.Molecular biology reports · 2024Review
- Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs.Cancer cell international · 2023Review
- Article
- Insights on the Role of Polyphenols in Combating Cancer Drug Resistance.Biomedicines · 2023Review
- Preventive and therapeutic effects of green tea on lung cancer: a narrative review of evidence from clinical and basic research.Journal of thoracic disease · 2022Review
- Green Tea Catechins: Nature's Way of Preventing and Treating Cancer.International journal of molecular sciences · 2022Review
- Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): A Time for a New Player in the Treatment of Respiratory Diseases?Antioxidants (Basel, Switzerland) · 2022Review
- Identification of Differentially Expressed Mirna by Next Generation Sequencing in Locally Advanced Breast Cancer Patients of South Indian Origin.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Chemical Structure, Sources and Role of Bioactive Flavonoids in Cancer Prevention: A Review.Plants (Basel, Switzerland) · 2022Review
- Article
- The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.Cellular & molecular biology letters · 2022Review
- Role of epigallocatechin-3- gallate in the regulation of known and novel microRNAs in breast carcinoma cells.Frontiers in genetics · 2022Article
- Effect of EGCG on bronchial epithelial cell premalignant lesions induced by cigarette smoke and on its CYP1A1 expression.International journal of molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer constitutes 85% of non-small cell lung cancer diagnosed cases. MicroRNAs are novel biomarkers that are capable of modulating multiple oncogenic pathways. Epigallocatechin-3-gallate (EGCG) is a potent chemopreventive and chemotherapeutic agent for cancer. We aimed to identify important known and putative novel microRNAs modulated by EGCG in A549 cells using next-generation sequencing and identify their gene targets. Preliminary analysis revealed an IC50 value of 309 μM with G0/G1 phase arrest at 40 μM EGCG treatment. MicroRNA profiling identified 115 known and 4 putative novel microRNAs in 40 μM and 134 known and 3 putative novel microRNAs in 100 μM EGCG-treated A549 cells. The top 10 up-expressed microRNAs were similar between the untreated control and EGCG-treated A549 cells. An up-expression in oncogenic microRNAs, which belong to broadly conserved seed families, were observed in untreated control and EGCG-treated A549 cells. Kyoto Encyclopedia of Genes and Genomes and Protein Analysis Through Evolutionary Relationships pathway analyses of the validated microRNA targeting genes strengthened the hypothesis that EGCG treatment can modulate microRNAs that play a significant role in the MAPK signaling pathway. Expression profile of microRNAs was validation by quantitative real time PCR of randomly selected microRNAs. This study identified signature microRNAs that can be used as novel biomarkers for lung cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.